942297-39-4Relevant academic research and scientific papers
First Cdc7 kinase inhibitors: Pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery
Menichincheri, Maria,Bargiotti, Alberto,Berthelsen, Jens,Bertrand, Jay A.,Bossi, Roberto,Ciavolella, Antonella,Cirla, Alessandra,Cristiani, Cinzia,Croci, Valter,D'Alessio, Roberto,Fasolini, Marina,Fiorentini, Francesco,Forte, Barbara,Isacchi, Antonella,Martina, Katia,Molinari, Antonio,Montagnoli, Alessia,Orsini, Paolo,Orzi, Fabrizio,Pesenti, Enrico,Pezzetta, Daniele,Pillan, Antonio,Poggesi, Italo,Roletto, Fulvia,Scolaro, Alessandra,Tato, Marco,Tibolla, Marcellino,Valsasina, Barbara,Varasi, Mario,Volpi, Daniele,Santocanale, Corrado,Vanotti, Ermes
experimental part, p. 293 - 307 (2009/10/09)
Cdc7 kinase is a key regulator of the S-phase of the cell cycle, known to promote the activation of DNA replication origins in eukaryotic organisms. Cdc7 inhibition can cause tumor-cell death in a p53-independent manner, supporting the rationale for devel
Heteroarylpyrrolopyridinones active as kinase inhibitors
-
Page/Page column 20, (2008/06/13)
Compounds represented by formula (I) wherein A, R1, R2, R3, R4, R5 and R6 are as defined in the specification or a pharmaceutically acceptable salt or solvate thereof, compositions thereof,
